These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8472810

  • 1. Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).
    Linssen P, Brons P, Knops G, Wessels H, de Witte T.
    Eur J Haematol; 1993 Mar; 50(3):149-54. PubMed ID: 8472810
    [Abstract] [Full Text] [Related]

  • 2. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells.
    Goselink HM, Williams DE, Fibbe WE, Wessels HW, Beverstock GC, Willemze R, Falkenburg JH.
    Blood; 1992 Aug 01; 80(3):750-7. PubMed ID: 1638026
    [Abstract] [Full Text] [Related]

  • 3. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C.
    Leukemia; 1994 Mar 01; 8(3):382-7. PubMed ID: 8127143
    [Abstract] [Full Text] [Related]

  • 4. In vitro sensitivity of hematopoietic progenitors to tiazofurin in refractory acute myeloid leukemia and in the blast crisis of chronic myeloid leukemia.
    Colovic M, Sefer D, Bogdanovic A, Suvajdzic N, Jankovic G, Atkinson HD, Milenkovic P.
    Cancer Lett; 2003 Jun 10; 195(2):153-9. PubMed ID: 12767523
    [Abstract] [Full Text] [Related]

  • 5. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D, Strife A, Atzpodien J, Clarkson BD.
    Cancer Res; 1987 Sep 15; 47(18):4788-94. PubMed ID: 3040231
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging.
    Rizzoli V, Mangoni L, Piovani G, Garau D, Caramatti C, Almici C, Carlo-Stella C.
    Leuk Lymphoma; 1993 Sep 15; 11 Suppl 1():109-12. PubMed ID: 8251884
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
    Geissler D, Gastl G, Aulitzky W, Tilg H, Gaggl S, Konwalinka G, Huber C.
    Leuk Res; 1990 Sep 15; 14(7):629-36. PubMed ID: 2388474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.